Products

Abatacept (TP-084CL)

Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077).      

Specifications
Classify
Protein therapeutics that interfere with a molecule or organism: Immunoregulation
Therapeutic
Abatacept
Trade Name
Orencia
Function
Fusion protein between extracellular domain of human cTLA4 and the modified Fc portion of human immunoglobulin G1; selective co-stimulation modulator; inhibits T-cell activation by binding to cD80 and cD86, thereby blocking interaction with cD28 and inhibiting autoimmune T-cell activation
Examples of Clinical Use
Rheumatoid arthritis (especially when refractory to TNFa inhibition)
References
Synonyms
CTLA4-Ig, CTLA4-IgG4m, CTLA4Ig, CTLA4IgG4m

For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Send Inquiry Now!
Name:
* Phone:
* E-mail Address:
* Service & Products Interested:
Project Description:
* Verification Code:
Please input "biolabs"(case insensitive) as verification code.
Contact Us to Order
Tel: 1-631-871-5806
Fax: 1-631-207-8356
Email:

45-1 Ramsey Road, Shirley, NY 11967, USA     Tel: 1-631-871-5806    Fax: 1-631-207-8356    Email:
Terms of Service-Privacy Policy     © 2007 - 2017 Creative-Biolabs All Rights Reserved